Cutellè Claudia, Balducci Claudia, Cereda Diletta, Fusco Maria Letizia, Iacobucci Davide, Perugini Jacopo, Pirro Fiammetta, Brivio Rinaldo, Bernasconi Davide Paolo, Ferrarese Carlo, Frigo Maura, Cavaletti Guido
Neuroimmunology Unit and Department of Neurology, San Gerardo Hospital, Monza, Italy; Experimental Neurology Unit, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; NeuroMI (Milan Center for Neuroscience), Milan, Italy.
Neuroimmunology Unit and Department of Neurology, San Gerardo Hospital, Monza, Italy.
J Neuroimmunol. 2022 Dec 15;373:577992. doi: 10.1016/j.jneuroim.2022.577992. Epub 2022 Oct 27.
The aim of the present study is to evaluate the composite role of k index in the initial assessment of Multiple Sclerosis (MS) patients and to select useful cut-offs exportable in clinical practice. We analysed CSF/serum samples of 140 patients and followed-up the CIS/MS subgroup for 7 years. Our results suggest κ index as a quantitative diagnostic and prognostic biomarker in MS, significantly associated to baseline lesion load and to successive clinical course. We propose k index ≥106 as a prognostic cut-off to select patients at major risk of relapse, potentially influencing initial therapeutic decisions.
本研究的目的是评估κ指数在多发性硬化症(MS)患者初始评估中的综合作用,并选择可应用于临床实践的有效临界值。我们分析了140例患者的脑脊液/血清样本,并对临床孤立综合征/多发性硬化症(CIS/MS)亚组进行了7年的随访。我们的结果表明,κ指数是MS中的一种定量诊断和预后生物标志物,与基线病变负荷和后续临床病程显著相关。我们建议将κ指数≥106作为预后临界值,以筛选出复发风险较高的患者,这可能会影响初始治疗决策。